主要终点是总生存率(OS)。
但它没有提高乳腺癌患者的总生存率。
But it doesn't improve breast cancer patients' overall survival rate.
主要效果终端指标为总生存率和症状进展时间。
Primary efficacy endpoints were overall survival and time to symptomatic progression.
预后参数评估包括总生存率和肿瘤相关生产率。
The outcome parameters assessed were overall survival and tumor-related survival.
共同的初级终点指标为总生存率和无进展生存率。
Coprimary end points were rates of overall and progression-free survival.
目的提高局部晚期鼻咽癌的局部控制率及总生存率。
Objective to improve local control rate and total survival rate of local later period nasopharyngeal carcinoma.
肺癌患者总生存率较低的主要原因是肿瘤细胞的转移。
The major cause of low survival rate in lung cancer patients is the metastasis of tumor cells.
总生存率及安全性被包括在研究的次要终点中进行评估。
Overall survival and safety are among the secondary endpoints that will be assessed in the trial.
尽管对已知的危险因素和随访措施改进不少，但胃癌患者的总生存率仍然很差。
The overall survival of gastric carcinoma patients remains poor despite improved control over known risk factors and surveillance.
二级终点包含了目标反应率，一年生存期，总生存率，化疗类型和安全性PFS评估。
Secondary endpoints included objective response rate, one-year survival rate, overall survival, PFS assessment by chemotherapy type and safety.
在确诊时的转化预示相对较好的预后，5年无进展生存率和总生存率分别达到66%和88%。
Transformation at the time of diagnosis portends a more favorable prognosis with 5-year PFS and OS rates of 66% and 88%, respectively.
医生发现，与只接受同步放化疗的患者相比，接受诱导治疗和同步放化疗的患者，其总生存率升高较小，但很显著。
Doctors found a small but significant increase in overall survival in the patients who received the induction therapy with chemoradiation versus the chemoradiation-only group.
在情况较差的病人组中，所有组的五年无病生存率以及估测十年总生存率在每个时间段内均相差不多，在84%到88%之间。
In the group with unfavorable features, 5-year event-free survival and estimates of 10-year overall survival were similar in all treatment groups and for each time period, ranging from 84% to 88%.
观察等待的患者在确诊后的前50个月内与相对照的背景人群有相似的总生存率（P<0.7），但是在50个月后死亡风险升高（P<0.001）。
The WAW patients and a matched backgroundpopulation had similar OS during the first 50 months after diagnosis(P = 0·7), but WAW patients had increased risk of death after 50 months (P < 0·001).
10年累计发生组织学转变的累计风险为22%（95%CI 15-29），在发生转化后3年的总生存率是71%（95% CI58-87%）。
The 10-year cumulative risk of histological transformation was 22% (95%CI 15-29) and the 3-year OS after transformation was 71% (95%CI 58-87%).
无论如何，除了90年代初期十分高龄的患者总的生存率还是都有所提高。
However, survival has improved in all but the very oldest ages since the early 1990s.
两组患者的5年总的生存率都接近70%以及无复发的生存率大约为62%。
In both groups, overall 5-year survival rate was approximately 70% and recurrence-free survival rate was about 62%.
两组患者的5年总的生存率都接近70%以及无复发的生存率大约为62%。
In both groups, overall 5-year survival rate was approximately 70% and recurrence-free survival rate was about 62%.
应用推荐